Palvella Therapeutics (NASDAQ:PVLA) Trading Up 14.4% on Analyst Upgrade

Palvella Therapeutics, Inc. (NASDAQ:PVLA) shares rose 14.4% during mid-day trading on Tuesday after Chardan Capital raised their price target on the stock from $210.00 to $240.00. Chardan Capital currently has a buy rating on the stock. Palvella Therapeutics traded as high as $125.90 and last traded at $126.65. Approximately 16,355 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 306,164 shares. The stock had previously closed at $110.66.

Several other equities research analysts have also recently weighed in on the company. Canaccord Genuity Group increased their price objective on Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. UBS Group reaffirmed a “buy” rating and set a $143.00 target price on shares of Palvella Therapeutics in a research report on Monday, December 15th. Oppenheimer reiterated an “outperform” rating and set a $200.00 target price on shares of Palvella Therapeutics in a research note on Monday, December 15th. BTIG Research increased their price target on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Finally, TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $198.07.

Insiders Place Their Bets

In other news, Director Elaine J. Heron bought 2,400 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average cost of $125.00 per share, for a total transaction of $300,000.00. Following the completion of the purchase, the director owned 47,812 shares of the company’s stock, valued at $5,976,500. This trade represents a 5.28% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director George M. Jenkins bought 4,000 shares of Palvella Therapeutics stock in a transaction that occurred on Friday, February 27th. The stock was purchased at an average cost of $125.00 per share, with a total value of $500,000.00. Following the completion of the transaction, the director owned 187,171 shares of the company’s stock, valued at $23,396,375. This trade represents a 2.18% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

Hedge funds have recently made changes to their positions in the business. Archer Investment Corp bought a new position in shares of Palvella Therapeutics during the 3rd quarter worth about $28,000. Group One Trading LLC increased its stake in Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after acquiring an additional 200 shares during the period. Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics in the third quarter worth about $36,000. JPMorgan Chase & Co. raised its position in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Palvella Therapeutics during the second quarter worth about $85,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Price Performance

The business’s 50 day simple moving average is $105.80 and its 200 day simple moving average is $91.85. The stock has a market cap of $1.43 billion, a P/E ratio of -32.45 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.13). Research analysts predict that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current year.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.